feedback

Faculty

Marcus Maurer
Marcus Maurer, MD (Moderator)

Charité – Universitätsmedizin Berlin
Berlin, Germany

Mark Lebwohl
Mark Lebwohl, MD (Course Director)

Icahn School of Medicine at Mount Sinai
New York, New York, USA

Emma Guttman
Emma Guttman, MD, PhD

Icahn School of Medicine at Mount Sinai Medical Center
New York, New York, USA

Accredited by

Oakstone Publishing, LLC

View Activity Materials

Activity Details

Credit Types:CME
Credit Amount:0.75 Credits
Release Date:2016-Dec-19
Expiration Date:2017-Dec-18
Estimated Time for Completion:45 minutes
Registration Required:No
Cost:Free of Charge

Funding Disclosure

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Description & Educational Objectives

In this activity, experts in atopic dermatitis discuss the immunopathogenic mechanisms contributing to atopic dermatitis (AD), how a greater understanding of these mechanisms have led to new targeted therapies, and how these therapies may be used once available.

Upon completion of this activity, participants should be better able to:

  • Describe the immunopathogenic mechanisms of atopic dermatitis (AD) and the rationale for targeting the relevant cytokines
  • Describe recent clinical data evaluating emerging targeted therapies for moderate or severe AD
  • Discuss the future clinical implications of data evaluating emerging targeted therapies and how evolving treatment strategies may apply to everyday practice

Target Audience

This activity has been designed to meet the educational needs of dermatologists, immunologists, allergists, and other clinicians involved in the treatment of atopic dermatitis.

Faculty & Disclosure / Conflict of Interest Policy

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Interviewees

Marcus Maurer, MD (Moderator)
Director of Research and Professor of Dermatology and Allergy
Department of Dermatology and Allergy
Charité – Universitätsmedizin Berlin
Berlin, Germany

Marcus Maurer, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Bayer AG; Genentech; Moxie Pharmaceuticals pvt. ltd; Shire Plc; and Uriach.

Grant/Research Support from Almirall Hermal GmbH; Bayer AG; Biofrontera AG; Essex Pharma GmbH; Genentech; GlaxoSmithKline Plc; Leo Pharma UK; Menarini Pharma UK; Moxie Pharmaceuticals pvt. ltd; MSD; Novartis Pharmaceuticals; Recordati Pharma; Sanofi-Aventis; Schering AG; Schering-Plough Corporation; Shire Plc; SymbioPharm GmbH; UCB Pharma Ltd; Uriach; and ViroPharma Inc.

Honoraria from Almirall Hermal GmbH; Bayer AG; Biofrontera AG; Essex Pharma GmbH; Genentech; GlaxoSmithKline Plc; Leo Pharma UK; Menarini Pharma UK; Moxie Pharmaceuticals pvt. ltd; MSD; Novartis Pharmaceuticals; Recordati Pharma; Sanofi-Aventis; Schering AG; Schering-Plough Corporation; Shire Plc; SymbioPharm GmbH; UCB Pharma Ltd; Uriach; and ViroPharma Inc.

Advisory Board for Bayer AG; Genentech; Moxie Pharmaceuticals pvt. ltd; Shire Plc; and Uriach.

Mark Lebwohl, MD (Course Director)
Professor and Chairman, Kimberly & Eric J Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York, USA

Mark Lebwohl, MD, has a financial interest/relationship or affiliation in the form of:

Grant/Research Support from AbGenomics International Inc.; Amgen Inc; Anacor Pharmaceuticals Inc.; Boehringer-Ingelheim; Celgene Ltd; Eli Lilly and Company; Ferndale Pharmaceuticals Ltd; Janssen Biotech, Inc.; Kadmon Corporation; Leo Pharma UK; MedImmune, LLC; Novartis Pharmaceuticals; Pfizer Inc; Sun Pharmaceutical Industries Limited; and Valeant Pharmaceuticals International, Inc.

Emma Guttman, MD, PhD
Professor of Medicine and Clinical Immunology
Vice Chair, Department of Dermatology
Director, Center for Excellence in Eczema
Director, Laboratory of Inflammatory Skin Diseases
Icahn School of Medicine at Mount Sinai Medical Center
New York, New York, USA

Emma Guttman, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant for AbbVie; Almirall Ltd; Anacor Pharmaceuticals Inc.; Asana BioSciences LLC; Celgene Ltd; Dermira; Eli Lilly and Company; Galderma (UK) Ltd; GlaxoSmithKline Plc; Glenmark Pharmaceuticals Inc.; Kyowa Hakko Kirin Co., Ltd.; LEO Pharma UK; MedImmune, LLC; Mitsubishi Tanabe Pharma; Novartis Pharmaceuticals; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sanofi-Aventis; Stiefel Laboratories; and Vitae Pharmaceuticals.

Grant/Research Support from Celgene Ltd; Eli Lilly and Company; LEO Pharma UK; MedImmune, LLC; Novartis Pharmaceuticals; and Regeneron Pharmaceuticals, Inc.

Advisory Board for Asana BioSciences LLC; Celgene Ltd; Dermira; Galderma (UK) Ltd; GlaxoSmithKline Plc; MedImmune, LLC; Novartis Pharmaceuticals; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sanofi-Aventis; Stiefel Laboratories; and Vitae Pharmaceuticals.

Medical Director

Christy Rohani, PhD
PeerVoice

Christy Rohani, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and PeerVoice. Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 70% is needed.

Media: Internet
Release and Expiration Dates: December 19, 2016 - December 18, 2017
Time to Complete: 45 minutes

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.